We are advancing a growing portfolio of off-the-shelf, optimally engineered NK cell therapy candidates that express not only a specific tumor antigen targeted CAR, but also have undergone different gene edits (e.g. CISH KO and CD38 KO) and additional construct features including a TNF-related apoptosis-inducing ligand variant (TRAILv) targeting the death receptor pathway via DR4 or DR5.
This pioneering approach has the clear goal to maximize the cytotoxic potential, metabolic health and persistence of the engineered NK cells.
| Program | Construct Targets and Enhancements | Indication | Research | Lead Optimization | IND Enabling |
|---|---|---|---|---|---|
| ONKT102 | CD38 CAR (fully human, optimized affinity) +/- DR5 TRAILv CISH KO CD38 KO (+ IL-6R Ab) | Relapsed / Refactory Multiple Myeloma | 100 | 100 | 10 |
| ONKT104 | CLL-1 CAR (humanized) +/- DR4 TRAILv CISH KO (+/- 2nd CAR) | AML | 90 |
| ONKT103 | MUC-1 CAR (tumor associated) +/- DR5 TRAILv CISH KO (+/- KO inhibitory NK receptors) | Ovarian, NSCLC, Breast | 90 |
We have also initiated two programs focused on the potential of highly functional CISH KO NK cells, namely:
- ONKT105, exploring CISH KO cord blood derived NK cells
- ONKT106, exploring CISH KO iPSC derived NK cells
Scroll left to right to view pipeline
